MedTrace Logo

Erlotinib in Treating Patients With Barrett Esophagus

NCT00566800 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with Barrett esophagus.

Conditions

  • Esophageal Cancer
  • Precancerous Condition

Interventions

DRUG

erlotinib hydrochloride

OTHER

laboratory biomarker analysis

PROCEDURE

biopsy

Sponsors & Collaborators

  • Kansas City Veteran Affairs Medical Center

    lead FED

Principal Investigators

  • Joaquina C. Baranda, MD · Kansas City Veteran Affairs Medical Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00566800 on ClinicalTrials.gov